Reta Birhane, Mohammed Abdurehman E, Tesfaye Kiya Girum, Adissu Wondimagegn, Shenkute Tilahun Y
Department of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia.
Department of Medical Laboratory Sciences, Wollo University, Dessie, Ethiopia.
Ann Med Surg (Lond). 2023 Jul 17;85(8):3887-3893. doi: 10.1097/MS9.0000000000001084. eCollection 2023 Aug.
Tuberculosis (TB) is a significant public health problem affecting one-third of the world's population. In 2021, 1.6 million people died from TB. TB is the 13th leading cause of death and the second leading cause of infectious death after coronavirus disease 2019. Most anti-TB drugs affect hematological parameters in patients.
This longitudinal prospective study was conducted from 03 January to 30 December 2019. Patients who completed a course of TB treatment were candidates for analysis. Sputum and blood samples were collected from each study participant and analyzed by the Gene X-pert machine and a HumaCount 30 hematology analyzer (Human GmbH). SPSS version 20 and R programming software version 4.2.3 were used for data analysis. Friedman's test was used to assess statistical significance. -values less than 0.05 were considered statistically significant.
A total of 148 patients who completed the course of TB treatment correctly were a candidate for final analysis. Ninety-one (61.5%) study participants were male; the median age was 27.6±9.8 years. Moreover, most of the study participants (84.4%) had pulmonary TB. Most of the hematological parameters had changed in the phases of TB treatment. After anti-TB treatment, there is a significant difference in hematological parameters in red blood cell count, hemoglobin concentration, hematocrit percentage, platelet count, and white blood cell count.
Anemia and leucopenia are the most significant problems after TB treatment. Regular checking of these parameters is essential for the patient.
结核病（TB）是一个严重的公共卫生问题，影响着世界三分之一的人口。2021年，有160万人死于结核病。结核病是第13大死因，也是仅次于2019冠状病毒病的第二大感染性死因。大多数抗结核药物会影响患者的血液学参数。
本纵向前瞻性研究于2019年1月3日至12月30日进行。完成结核病治疗疗程的患者为分析对象。从每位研究参与者采集痰液和血液样本，并通过Gene X-pert机器和HumaCount 30血液分析仪（Human GmbH）进行分析。使用SPSS 20版和R编程软件4.2.3版进行数据分析。采用Friedman检验评估统计学显著性。P值小于0.05被认为具有统计学显著性。
共有148名正确完成结核病治疗疗程的患者作为最终分析对象。91名（61.5%）研究参与者为男性；中位年龄为27.6±9.8岁。此外，大多数研究参与者（84.4%）患有肺结核。大多数血液学参数在结核病治疗阶段发生了变化。抗结核治疗后，红细胞计数、血红蛋白浓度、血细胞比容百分比、血小板计数和白细胞计数等血液学参数存在显著差异。
贫血和白细胞减少是结核病治疗后最显著的问题。定期检查这些参数对患者至关重要。
